尿液DKK3可识别短期eGFR下降风险的CKD患者
该前瞻性研究评估了不同病因CKD患者基线及年度随访的尿DKK3水平与eGFR变化的关系。结果显示,基线尿DKK3/肌酐>4000 pg/mg与12个月内eGFR年均下降7.6%独立相关,且尿DKK3预测肾功能下降优于eGFR或白蛋白尿。
要点
- 尿DKK3/肌酐>4000 pg/mg独立预测12个月eGFR下降7.6%。
- 尿DKK3预测肾功能下降优于eGFR或白蛋白尿。
- 尿DKK3水平与肾活检小管间质纤维化程度相关。
核心结论
- 尿DKK3水平可识别未来12个月eGFR下降高风险的患者,不受肾损伤病因影响,且优于现有生物标志物。
研究设计与样本
- 前瞻性评估不同病因CKD患者基线及年度随访的eGFR和尿DKK3水平,并在普通人群样本、诊断性肾活检患者及治疗中的IgA肾病患者中测量尿DKK3。
主要发现
- CKD患者基线尿DKK3/肌酐中位数显著高于普通人群样本(431 vs 33 pg/mg)。
- CKD队列中,尿DKK3/肌酐>4000 pg/mg经多因素调整后与12个月内eGFR年均下降7.6%独立显著相关。
- 尿DKK3较eGFR或白蛋白尿alone显著改善肾功能下降的预测。
- 尿DKK3/肌酐水平与肾活检小管间质纤维化程度相关。
- IgA肾病患者中,尿DKK3升高与6个月内显著eGFR下降相关,而稳定或下降则预示较好病程。
关键数值与推荐
- 尿DKK3/肌酐>4000 pg/mg与12个月内eGFR年均下降7.6%独立相关。
- CKD患者基线尿DKK3/肌酐中位数为431 pg/mg,普通人群为33 pg/mg。
临床怎么用
- 可考虑检测尿DKK3/肌酐以识别短期eGFR下降高风险的CKD患者,辅助监测疾病进展和评估干预效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The individual course of CKD may vary, and improved methods for identifying which patients will experience short-term eGFR loss are needed. Assessing urinary Dickkopf-3 (DKK3), a stress-induced tubular epithelia-derived profibrotic glycoprotein, may provide information about ongoing tubulointerstitial fibrosis and short-term eGFR loss. METHODS: To investigate urinary DKK3's potential as a biomarker of short-term eGFR loss (over 12 months), we prospectively assessed eGFR and urinary DKK3 levels in patients with CKD of various etiologies at baseline and annual follow-ups. We also measured urinary DKK3 in a general population sample and patients with diagnostic kidney biopsies or IgA nephropathy under treatment. RESULTS: Median urinary DKK3-to-creatinine concentration at baseline was significantly higher in patients with CKD than the general population sample (431 versus 33 pg/mg). In the CKD cohort, having a urinary DKK3-to-creatinine level >4000 pg/mg was independently and significantly associated after multiple adjustments with mean annual decline in eGFR of 7.6% over 12 months. Urinary DKK3 significantly improved prediction of kidney function decline compared with eGFR or albuminuria alone. Urinary DKK3-to-creatinine levels were related to the extent of tubulointerstitial fibrosis in kidney biopsies. In patients with IgA nephropathy, a rise in urinary DKK3 was associated with significant eGFR decline within 6 months, whereas stable or decreasing urinary DKK3 indicated a more favorable course. CONCLUSIONS: Urinary DKK3 levels identify patients at high risk for eGFR decline over the next 12 months regardless of the cause of kidney injury and beyond established biomarkers, potentially providing a tool to monitor CKD progression and assess effects of interventions.
引用
- Zewinger S, Rauen T, Rudnicki M, et al. Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss. J Am Soc Nephrol. 2018. PMID: 30279273. doi:10.1681/ASN.2018040405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。